Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography

Description

The goal of this observational trial is to determine the resting cardiac output (CO) using transthoracic echocardiography (TTE) in a cohort of people with untreated preeclampsia, and a cohort of healthy normotensive pregnant people.

Conditions

Preeclampsia

Study Overview

Study Details

Study overview

The goal of this observational trial is to determine the resting cardiac output (CO) using transthoracic echocardiography (TTE) in a cohort of people with untreated preeclampsia, and a cohort of healthy normotensive pregnant people.

Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography

Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography

Condition
Preeclampsia
Intervention / Treatment

-

Contacts and Locations

Boston

Brigham and Women's Hospital, Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Preclampsia definition: People with preeclampsia will be recruited at the time of diagnosis or suspected diagnosis of preeclampsia, according to accepted definitions of preeclampsia. Preeclampsia with severe features will be defined using the American College of Obstetrics and Gynecology definition.
  • 2. Nulliparous, singleton pregnancy,
  • 3. ≥20 weeks gestation
  • 4. without any preexisting cardiovascular, hepatic, or respiratory problems,
  • 5. No preexisting uterine abnormality including benign tumors, or placental adhesive disorder,
  • 6. Not in labor,
  • 7. Not with prior to treatment for preeclampsia,
  • 8. Body mass index ≤ 40 kg/m2, age 18 to 50 years.
  • 1. American Society of Anesthesiologists (ASA) Classification II with no significant medical or surgical illness,
  • 2. Nulliparous (first pregnancy beyond 20 week's gestation)
  • 3. Non-smokers, singleton pregnancy
  • 4. Not having ruptured membranes
  • 5. No uterine abnormalities
  • 6. No placentation abnormalities.
  • 7. Not receiving any vasoactive medication including salbutamol
  • 8. Not on thyroid replacement hormones
  • 1. Multiparous, multiple pregnancy,
  • 2. Previous cardiovascular, hepatic or respiratory problems
  • 3. Gestational diabetes,
  • 4. Hemodynamic or neurologically unstable patient
  • 5. Unable to tolerate a 30-minute ultrasound examination (TTE)
  • 6. Age less than 18 or greater than 50 years
  • 7. BMI \> 40 kg/m2,
  • 8. Gestation \< 20 weeks.
  • 1. Current administration of vasoactive drugs including salbutamol
  • 2. Current administration of thyroxine
  • 3. Pre-existing or gestational diabetes
  • 4. Tobacco use
  • 5. Pre-existing or gestational hypertension or preeclampsia
  • 6. Known uterine abnormality, in labor or ruptured membranes
  • 7. Unable to tolerate a 30-minute ultrasound examination (TTE)
  • 8. Age less than 18 or greater than 50 years
  • 9. BMI \> 40 kg/m2,
  • 10. Gestation \< 20 weeks.

Ages Eligible for Study

18 Years to 55 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Brigham and Women's Hospital,

Michaela Farber, MD, PRINCIPAL_INVESTIGATOR, BWH

Alicia T Dennis, MBBS PhD MPH, STUDY_DIRECTOR, University of Melbourne, Australia

Study Record Dates

2025-10-11